Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Raziel & Fosun Start Phase 3 Trial in China for Submental Fat Reduction Treatment
Details : RZL-012 is an injectable lipolytic drug, works by destroys fat cells and reduces fat volume, currently being developed for the reduction of unwanted submental fat in adults
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2025
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-label Study That Will Test a Second Treatment Session of RZL-012.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2023
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2022
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 20, 2022
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZL-012
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2022
Lead Product(s) : RZL-012
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of RZL-012 on Submental Fat Reduction
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 30, 2021
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZL-012
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RZL-012 for Dercum's Disease Lipomas
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2020
Lead Product(s) : RZL-012
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 12, 2019
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZL-012
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : University of Arizona
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2018
Lead Product(s) : RZL-012
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : University of Arizona
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Spaulding Clinical, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2017
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Spaulding Clinical, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable